Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Cannabis Bioscience International Holdings (CBIH) EBT Margin (2022 - 2026)

Cannabis Bioscience International Holdings' EBT Margin history spans 5 years, with the latest figure at 928.47% for Q1 2026.

  • On a quarterly basis, EBT Margin rose 8758.0% to 928.47% in Q1 2026 year-over-year; TTM through Feb 2026 was 431.09%, a 34337.0% decrease, with the full-year FY2025 number at 184.02%, up 1576.0% from a year prior.
  • EBT Margin hit 928.47% in Q1 2026 for Cannabis Bioscience International Holdings, down from 186.06% in the prior quarter.
  • Over the last five years, EBT Margin for CBIH hit a ceiling of 24.08% in Q2 2024 and a floor of 1016.05% in Q1 2025.
  • Historically, EBT Margin has averaged 413.01% across 5 years, with a median of 323.53% in 2025.
  • Biggest five-year swings in EBT Margin: surged 61898bps in 2024 and later tumbled -70394bps in 2025.
  • Tracing CBIH's EBT Margin over 5 years: stood at 266.27% in 2022, then skyrocketed by 44bps to 148.26% in 2023, then soared by 38bps to 92.03% in 2024, then crashed by -102bps to 186.06% in 2025, then crashed by -399bps to 928.47% in 2026.
  • Business Quant data shows EBT Margin for CBIH at 928.47% in Q1 2026, 186.06% in Q4 2025, and 380.79% in Q3 2025.